Owkin, an artificial intelligence (AI)-driven biotech, and Proscia, a provider of AI pathology solutions, have partnered to enhance Microsatellite instability (MSI) testing for colorectal cancer (CRC).
The collaboration will integrate Owkin’s next-generation AI diagnostic platform MSIntuit CRC v2 with Proscia’s Concentriq software platform.
This integration aims to improve MSI screening and will be included in Proscia’s precision medicine AI portfolio, helping labs meet the growing demand for CRC testing.
It is said to help in the pre-screening of patients with microsatellite stable (MSS) / proficient mismatch repair (pMMR) in colorectal tumours.
A Research Use Only (RUO) version of MSIntuit CRC v2 will soon be available in the US on Proscia’s Concentriq platform for impact analysis. Additional products and solutions will be integrated and accessible in the US and Europe as they become available.
Owkin CEO Thomas Clozel said: “We are thrilled to partner with Proscia and execute on our shared vision of harnessing the power of AI to transform medical research and diagnosis. Together, we will expand access to our digital diagnostics for patients globally.”
MSIntuit CRC v2, which analyses biopsy samples, improves upon the CE-IVD-certified MSIntuit CRC.
France-based Owkin said the original version offers a 95% sensitivity, matching standard tests, and can exclude nearly half of CRC patients from pMMR/MSI testing.
By integrating MSIntuit CRC v2 into Proscia’s Concentriq platform, part of their precision medicine AI portfolio, this collaboration could increase access to AI diagnostics in pathology labs.
Concentriq is used as an enterprise pathology platform that supports major labs in managing all aspects of their operations.
Proscia CEO David West said: “Our shared focus on advancing pathology from drug discovery to diagnostics uniquely positions us to unlock the potential of AI on novel therapies and treatment decisions, and our growing base of customers will ensure that breakthroughs are translated into the clinic to benefit patients.”
Through the collaboration, Owkin has joined the Proscia Ready partner alliance, which supports labs and life sciences organisations in adopting AI-powered digital pathology.
In November 2023, Owkin partnered with Sectra to expand the reach of AI diagnostics for CRC. The following month, the biotechnology firm collaborated with Cerba Path on AI-based breast and colorectal cancer diagnosis.
